propafenone

(redirected from Rythmol sr)

propafenone

 [pro″pah-fe´nōn]
a sodium channel blocking agent that acts on the Purkinje fibers and the myocardium; used as the hydrochloride salt in treatment of life-threatening arrhythmias, administered orally.

propafenone

/pro·pa·fe·none/ (pro″pah-fe´nōn) a sodium channel blocking agent acting on the Purkinje fibers and the myocardium; used as the hydrochloride salt as an antiarrhythmic.

propafenone

Rythmol® Cardiology A beta-blocking antiarrhythmic for severe ventricular and supraventricular arrhythmias–A Fib, V Tach, conduction block, HTN Complications Ventricular proarrhythmia; conduction defects Adverse effects Neurologic–headache, dizziness, paresthesias, peripheral neuropathy, GI–eg, N&V, anorexia. See Antiarrhythmic, Beta-blockers.

propafenone

A drug used to treat heart irregularities (arrhythmias). A brand name is Arythmol.

propafenone (prō´pəfē´nōn),

n brand name: Rythmol;
drug class: antidysrhythmic (Class IC);
action: able to slow conduction velocity; reduces cardiac muscle membrane responsiveness; inhibits automaticity; increases ratio of effective refractory period to action potential duration; β-blocking activity;
use: documented life-threatening dysrhythmias.
References in periodicals archive ?
M2 EQUITYBITES-September 11, 2017-Glenmark Pharmaceuticals granted final FDA approval to market generic version of Rythmol SR
M2 PHARMA-September 11, 2017-Glenmark Pharmaceuticals granted final FDA approval to market generic version of Rythmol SR
On January 3, 2011, Par Pharmaceutical successfully launched the 225mg, 325mg, and 425mg strengths of propafenone SR capsules, the generic version of GlaxoSmithKline's Rythmol SR [R] .
Linde predicted that if the new REVERSE findings are confirmed in the much larger ongoing Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy (MADIT-CRT) trial and Rythmol SR Atrial Fibrillation Trial (RAFT), as she expects, the indications for CRT will broaden to incorporate the large population of patients with class I and II heart failure.
for infringement of United States Patent 5,681,588, which expires in 2014 and relates to Reliant's Rythmol SR product.
GlobalData's pharmaceuticals report, Rythmol SR (Atrial Fibrillation) - Analysis and Forecasts to 2022 provides Rythmol SR global sales estimates.
The company added that Propafenone Hydrochloride Extended-Release Capsules USP, 225 mg, 325 mg, 425 mg is the generic version of GlaxoSmithKline's Rythmol SR.
145 GlaxoSmithKline Rythmol SR 00173078801 $39,321,455
Ernest Mario, Reliant's Chairman and Chief Executive Officer noted, "Our acquisition of the Rythmol product family, particularly the recently approved Rythmol SR (propafenone HCl extended release) dosage form, represents a significant expansion of Reliant's cardiovascular product franchise.
Angotti led the expansion of a mass market and specialty sales force in the United States to promote both Lovaza, a treatment for hypertriglyceridemia, and Rythmol SR, a treatment for atrial fibrillation.
is shipping the 225-mg, 325-mg and 425-mg strengths of propafenone SR capsules, the generic version of GlaxoSmithKline PLC's Rythmol SR.
The company said the propafenone SR capsules are the generic version of GlaxoSmithKline's Rythmol SR.